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Summary A retrospective analysis was performed upon 175 patients with Non-Hodgkin's Lymphoma involv-
ing the gastrointestinal tract and entered into BNLI trials and studies between 1974-1988. Malignant
histiocytosis of the intestine (MHI), which was present in 16 patients, was associated with a survival of less
than 25% at 18 months, and probably accounted for the poor survival of patients with jejunal involvement.
Histopathological evidence of tumour origin from mucosa-associated lymphoid tissue (MALT) was found in
50% of patients with gastric involvement and in 27% of those with intestinal involvement. The overall survival
of the series as a whole was 44% at 10 years. Multivariate analysis identified evidence of tumour origin from
MALT as the only factor to attain prognostic significance in patients with gastric involvement, and clinical
stage and the presence of MHI as the only factors to attain prognostic significance in patients with intestinal
involvement. It is suggested that there is a need for a large multicentre prospective study of GIT lymphoma.
Non-Hodgkin's lymphoma of the gastrointestinal tract (GIT)
is rare, accounting for less than five per cent of all GIT
malignancies (Loehr et al., 1969; Gupta et al., 1981). How-
ever, apart from the tonsil the GIT is the commonest site for
extranodal lymphomas (Freeman et al., 1972; Gospodarowicz
et al., 1987). The organisation and histological features of the
lymphoid tissue in the GIT differs from that of peripheral
lymph nodes, occurring in the form of mucosa associated
lymphoid tissue (MALT) which has unique immuno-physio-
logical characteristics. The lymphoid tissue of MALT may be
a normal tissue component, as in the intestine; or it may be
acquired as a consequence of an autoimmune or
inflammatory disorder, as in the stomach (Isaacson et al.,
1988; Dixon et al., 1988). Lymphomas of the GIT may
therefore behave differently from primary nodal disease.
Because of this, and also because of the difficulty in applying
the standard staging classification, these lymphomas may
require different management strategies to nodal NHL.
A retrospective analysis ofpatients entered into the various
clinical trials and studies undertaken by the BNLI (British
National Lymphoma Investigation) over 14 years is reported
in this work, in an attempt to define the natural history of
this group of lymphomas, identify prognostic factors, and
evaluate the effects of therapy. This may help to define the
questions that need to be addressed in future studies.
Methods
The series consisted of 175 patients with primary gastrointes-
tinal (GI) NHL, namely those whose main presenting feature
was related to the GI tract or in which the predominant
lesion was clearly in the GI tract, who were entered into
BNLI studies between 1974 and 1988. Diagnostic material
was obtained either at laparotomy or by endoscopic biopsy.
Patients received either full, partial, or no surgical resection,
followed by either chemotherapy (CT), radiotherapy (RT),
both of these modalities in combination (RT + CT), or no
further treatment, according to the protocol of the time.
Surgery was not always performed at the referral centre and
operation details were unavailable for 42 patients. Data con-
cerning pre-existing conditions (malabsorption, inflammatory
bowel disease etc.) were too incomplete for meaningful
analysis.
The histopathology of all patients was reviewed by two
members the BNLI pathology panel (KAM,MHB), with the
exception of 4 patients whose sections were unavailable for
analysis. The analysis included histopathological subtyping
and grading according to the BNLI classification (Bennett et
al., 1974) and the Working Formulation (WF) (NCI., 1982).
Especial emphasis was placed on the identification of lym-
phomas of the intestine with histological features typical of
the entity described by Isaacson and Wright (1978) as a
malignant histiocytosis of the intestine (MHI), and later dem-
onstrated to be T-cell lymphoma (Isaacson et al., 1985),
termed by some as enteropathy associated T-cell lymphoma.
Special emphasis was also placed upon the identification of
lymphomas with histological features typical ofmultiple lym-
phomatous polyposis (MLP: Isaacson et al., 1984), and of
lymphomas with histological features indicating an origin
from mucosa-associated lymphoid tissue (MALT) (Isaacson
et al., 1983; Isaacson & Wright, 1984; Isaacson, 1990);
briefly, these were the presence of a superficial plasma cell-
rich zone, the presence of an irregular B-cell population
termed centrocyte-like cells, and the occurrence of lympho-
eopithelial lesions. Cases were classified as high grade MALT
lymphoma when areas of confluent large cell cytology were
found in association with other histological features typical
of MALT lymphomas. MALT status was not evaluable in
nine patients. In all cases of high grade T and B cell lym-
phoma cell lineage was confirmed by paraffin section
immunocytochemistry for T-cell restricted antigens recog-
nised by UCHLI (CD45RO; Norton et al., 1986), polyclonal
CD3 (Mason et al., 1989), and by the B-cell restricted antigen
recognised by L26 (CD20; Ishii et al., 1984; Mason et al.,
1990).
Patients were staged according to the Ann Arbor
classification (Crowther et al., 1982), and also where possible
retrospectively according to the Manchester classification de-
scribed by Blackledge et al. (1979). Patients were classified as
stage 4 if disease was present in marrow, liver, lung, pleura,
bone or other extranodal site in addition to disease in the
stomach or intestine.
Survival was calculated by the life-table method, the curves
including deaths from all causes, and statistical comparison
of curves by means of the log-rank test as described by Peto
et al (Peto et al., 1971). Multivariate analysis was performed
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by the use of a stepwise proportional hazards model (Cox,
1972).
Patients characteristics
The age, sex, and stage distribution in the series, together
with the frequency of mediastinal involvement, systemic 'B'
symptoms, and abnormal haematological parameters are
shown in Table I.
The sites of GIT disease are shown in Table II. The
stomach was involved in 45% of patients, the intestine in
54%, and both together in 1%. The most frequent sites of
intestinal involvement were ileum (36%), jejunum, (21%),
and colon (14%). Two separate intestinal entities were
involved together in 11% of patients, (Ileum and caecum or
colon = 9%, Jejunum and caecum or colon = 2%): it was
uncertain from the data available as to whether spread by
direct extension was involved.
The commonest mode of presentation was abdominal pain
(38%) (Table III).
Diagnosis was by laparotomy in 90% and by endoscopic
biopsy in 10% of patients.
Complete surgical excision was performed in 63%, partial
surgical excision in 16%, and biopsy alone in 21% of the 133
patients for whom details of surgery were available.
Table m Mode of presentation
Abdominal pain 66 45%
Abdominal mass 15 10%
Obstruction 16 11%
GI bleeding 11 8%
Changed bowel habit 9 6%
Nausea, vomiting, anorexia or weight loss 16 11%
Perforation 7 5%
Incidental finding 4 3%
Anaemia I <1%
Dysphagia 1 <1%
(Unknown = 17%)
The treatment given is shown in Table IV. CHOP was
given to 57% of patients, Chlorambucil to 7%, RT to 15%,
RT + COP to 7%; one patient received COP and one patient
PACE BOM; 11% received surgery alone.
A comparison of characteristics between patients with gas-
tric and patients with intestinal involvement showed that
patients with intestinal involvement tended to be older, and
to have a higher frequency of stage 4 disease and of low
presentation lymphocyte counts, than patients with gastric
involvement.
Table I Patient characteristics
Total
Age
Sex
17-49
50+
M
F
Clinical stage
1
2
3
4
33
94
2
46
Mediastinal status
Not involved
Involved
Systemic 'B' symptoms
Absent 116
Present 57
(Unknown = 1%)
ESR
<50 113
50+ 26
(Unknown = 21%)
Albumin
35+ 96
<36 61
(Unknown = 10%)
Lymphocytes Total WBCS
1500+ 76
< 1500 74
(Unknown = 14%)
Haemoglobin
12+ 107
<12 57
(Unknown = 6%)
175
48
127
115
60
100%
27%
73%
66%
34%
19%
54%
1%
26%
167 95%
8 5%
67%
33%
81%
19%
61%
39%
51%
49%
65%
35%
Table II Sites of GIT disease
Extranodal site Stomach 78 45%
Intestine 95 54%
Stomach and intestine 2 1%
Intestinal sites Duodenum 4 4%
Jejunum 20 21%
Ileum 34 36%
Caecum/colon/rectum 26 27%
Ileum + caecum/colon 9 9%
Jejunum + caecum/colon 2 2%
Results
Histopathology
The results of the histopathological review are shown in
Tables V and VI. Most patients were classified as belonging
to the diffuse large cell subtype (41%) or to the MALT
subtype (35%); a further 9% were classified as MHI. Two
per cent of the series were classified as MLP. Evidence of
tumour origin from MALT was found in 50% of patients
with gastric involvement and 27% of patients with intestinal
involvement. Only 16% of the series were classified as grade
1. Histology by stage and site is shown in Tables VII and
VIII).
Table IV Treatment
CHOP 100 57%
Radiotherapy 27 15%
Surgery alone 20 11%
Radiotherapy and COP 13 7%
Chlorambucil 13 7%
COP 1 <1%
PACE-BOM I <1%
Table V Histopathological findings (a)
% of total
Subtype n series
MALT 62 35%
Malignant histiocytosis of the intestine 16 9%
(MHI)
Multiple lymphomatous polyposis (MLP) 4 2%
Othersa
Follicular (B + C) 2 1%
Diffuse lymphocyte (A) 2 1%
well-differentiated
Diffuse lymphoma (E) 4 2%
intermediate
Lymphoblastic (J) 6 3%
Diffuse mixed small lymphoid(F) 4 2%
and large cell
Diffuse large cell (G) 71 41%
Unclassified 4 2%
'BNLI classification (working formulation).778 J.E. MORTON et al.
Table VI Histopatho
GRADE
Grade I MALT
MLP
Other
Grade 2 MALT
MHI
Diffuse large o
Other
MALT
Evid
orig
Gastric involvement
Intestinal involvement
Table VII Histo
Stage I Stag
MALT 19 58% 30
MHI 2 6% 10
MLP 0 0 1
DLC 9 27% 43
Other 3 9% 10
Overall survival and causes ofdec
The overall survival of patients
44% at 10 years. Death was;
treatment in all cases with the e
these, five died from other caus
in three the cause of death wa
died with infection: one received
of the remaining 13, all receive
logical findings (b) survival of patients with jejunal involvement was probably
due to the high proportion of patients with MHI in this site,
16 since the survival of those patients with MHI was con-
4 28 (16%) siderably lower than patients of other histologies in the
8 jejunum (<10% compared to >50%, at 2 years), though
46 the difference was not significant.
16 There was no significant difference in survival between
ell 71 143 (84%) patients who received different treatments (CHOP,
10 RT + COP, RT, chlorambucil, or surgery alone). The sur-
vival of patients who had complete surgical excision was
lence of significantly higher than that of patients who had only partial
,in from Evaluable % excision or endoscopic biopsy (P = 0.014). For patients who
IALT patients MALT received complete surgical excision, survival was significantly
higher for those who received no further treatment than for
38 76 50% those who received CHOP or chlorambucil. However the 24 90 27% relationships between treatment and survival were not neces-
sarily causal, because of the tendency to give treatment in
situations when residual disease is suspected.
Systemic 'B' symptoms, low presentation lymphocyte count
and albumin and haemoglobin levels were all associated with
significantly reduced survival. The use of the Manchester
logy by stage staging system did not appear to result in any appreciably
e II Stages IIl/IV greater separation between the survival of different stages
32% 12 25% than the Ann Arbor classification.
11% 4 8% For patients with intestinal involvement there was a
1% 3 6% significant difference between the survival of patients of
46% 20 42% different stage, both according to the Ann Arbor
11% 9 19% classification and the Manchester staging system. For
patients with gastric involvement there was no sigificant
difference between the survival of patients of different stage
with either method.
7th
Multivariate analysis was performed on the series a
whole, and also on patients with gastric and intestinal
in the series as a whole was involvement separately (Table IX). For the series as a whole,
associated with NHL or its only stage and MALT status were significant prognostic
xception of eight patients; of factors (P = 0.0009 and 0.01 respectively). For patients with
es (four MI, one CVA), and gastric involvement, only MALT status was significant
.s uncertain. Fifteen patients (P = 0.02); for patients with intestinal involvement, only
I only RT, one only surgery: stage and the presence of MHI were significant (P = 0.001
d CT either as initial treat- and 0.006 respectively).
ment (eight CHOP, four RT + COP) or as salvage therapy
(one COP), and 12 were receiving CT at time of death (five
CHOP, one BEAM, one COP, 2RT + COP, one Chloram-
bucil, two Mitoxantrone).
Prognosticfactors
On univariate analysis the most markedly significant factors
related to overall survival were stage (P = 0.003) and MALT
status (P = 0.004), with localised stage and evidence of
tumour origin from MALT being associated with relatively
high survival. There was no significant difference in survival
between low and high grade MALT lymphoma (P> 0.4).
There was however a significant difference in survival
between high grade MALT lymphoma and diffuse large cell
lymphoma (P<0.04). There was no significant difference
between the overall survival of patients with gastric and
intestinal involvement. There was a significant difference in
the survival of patients with different sites of intestinal
involvement (P = 0.03), due mainly to the relatively high
survival of patients whose GIT involvement was confined to
the ileum and the poor survival of patients in whom it was
confined to the jejunum. The survival of patients with MHI
was very poor, being less than 25% at 18 months. The poor
Table IX Multivariate analysis
Entries
Variable
Stage
Symptoms
MALT status
Histological grade
Surgical excision
Treatment
Albumin level
HB level
Lymphocyte count
MHI statusa
Significant variables
Whole series
Gastric involvement
Intestinal involvement
Covariates
1, 2, 3/4
A, B
Present, Absent
1, 2
Excision, Biopsy only
CHOP, RT, RT + COP, Chlorambucil,
Surgery alone
<35gl[', 35+gl-'
<12gdl-', 12+gdl-'
<1.5 x 109l-', 1.5+ x 1091-'
Present, Absent
Stage (P = 0.0009), MALT status
(P = 0.01)
MALT status (P = 0.02)
Stage (P = 0.001), MHI status
(P =0.006).
aEntry in intestinal involvement analysis only.
Table VIII Histology by site
Stomach Duodenum Jejunum Ileo-colic Rectum
MALT 38 49% 2 (50%) 5 25% 15 24% 2 (29%)
MHI 0 - 0 - 11 55% 5 8% 0 -
MLP 0 - 0 - 2 10% 1 2% 0 -
DLC 30 38% 2 (50%) 2 10% 35 52% 2 (29%)
Other 10 13% 0 - 0 - 9 15% 3 (43%)GASTROINTESTINAL NON-HODGKIN'S LYMPHOMA 779
Survival curves for MALT status and stage are shown in
Figures la and lb for patients with gastric involvement and
in Figures 2a and 2b for patients with intestinal involvement.
The survival curve for MHI is shown in Figure 3.
Discussion
The site, age, and sex distribution of the present series were
similar to those described in previous reports (Loehr et al.,
1969; Contreary et al., 1980; Herrman et al., 1980; Kaufman
et al., 1984; Ampil, 1987; Kajanti et al., 1988), although some
investigators found small gut involvement to be relatively
more common (Blackledge et al., 1979; Makepeace et al.,
1987; Baildam et al., 1989); in the present series this was
possibly due to failure to refer patients with Stage IE/IIE
gastric lymphoma who had undergone complete resection. As
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in other reports abdominal pain was the commonest presen-
ting feature (Novak et al., 1979; Contreary et al., 1980;
Herrmann et al., 1980; Kaufman et al., 1984; Rao et al.,
1984; Bonadonna & Valagussa, 1986; Makepeace et al., 1987;
Kajanti et al., 1988; List et al., 1988; Jones et al., 1988).
Although comparisons of overall survival between different
published series do not take account of differences in risk
factors within the series, it is perhaps worth noting that the
overall survival of 44% at 5 years in the present series
compares favourably with previous reports, in which it
ranges from 33% to 55% (Rao et al., 1984; Bonadonna &
Valagussa, 1986; Ampil, 1987; Makepeace et al., 1987; Bail-
dam et al., 1989).
For those patients with gastric involvement, 50% had
histopathological evidence of tumour origin from MALT.
This frequency of occurrence was of the same order as that
reported by De las Heras et al. (1989) (51%) but differed
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Figure 1 a, The overall survival of patients with gastric involvement, with (Ml/M2) and without (N) evidence of tumour origin
from MALT. b, The overall survival of Stage 1, Stage 2 and Stage 3/4 patients with gastric involvement.
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Figure 2 a, The overall survival of patients with intestinal involvement, with (Ml/M2) and without (N) evidence of tumour origin
from MALT. b, The overall survival of Stage 1, Stage 2 and Stage 3/4 patients with intestinal involvement.
from that reported by Johnsson et al. (1990) (33%). The
survival of these patients was significantly higher than those
without evidence of tumour origin from MALT, as was also
reported by De las Heras et al. (1989).
The lack of any significant difference in survival between
different stages of disease in patients with gastric involvement
in the present series is surprising, particularly the low sur-
vival of patients with Stage IE disease. This may have been
due to the difficulties inherent in staging extranodal lym-
phomas (Blackledge et al., 1979; Green et al., 1981; Crowther
et al., 1982; Rao et al., 1984; Bonadonna & Valagussa, 1986;
Cajozzo et al., 1987) by the Ann Arbor method, which the
Manchester system was designed to circumvent. However no
significant difference was found when either the Ann Arbor
or the Manchester system was used, although it should be
observed that the latter system was applied retrospectively. It
is possible that the lack of any prognostic effect from stage in
patients with gastric involvement and its strong prognostic
effect found in patients with intestinal involvement may have
been due to the different origins of lymphoid tissue, and
hence histologic differences in the lymphomas arising in these
two organs. However, treatment of patients in the series was
preselected in respect of stage, with relatively aggressive
treatment usually being given to patients with advanced
stage, and less aggressive treatment given to those clinically
localised disease. It is possible that this procedure effectively
masked a prognostic effect of stage in patients with gastric
involvement, though this remains unproven.
Patients received a wide range of treatments, depending on
the BNLI protocols current at the time. Treatment groups
available for comparison were small, and in many cases
treatment was tailored to prognostic factors deemed to be
important at the time, including histological grade, stage, and
symptoms, thereby confounding the overall effects of therapy
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and making statistically valid inferences hazardous. Thus the
relatively high survival of patients who received complete
surgical resection alone, compared to the survival of those
who received CHOP or chlorambucil in addition, was prob-
ably due to the high proportion of patients in the former
group with evidence of MALT type gastric lymphoma, since
the survival of such patients was high in the series overall. In
general, it would appear that survival depended primarily
upon whether the extranodal involvement was ofthe stomach
or of the intestine, the stage of the patient, whether the
tumour originated from mucosa associated lymphoid tissue,
and whether the tumour was a malignant histiocytosis of the
intestine.
There is disagreement in the literature as to the need for
surgical debulking. Those in favour of it argue that physical
removal of as much tumour as possible reduces the risk of
complications, such as haemorrhage or perforation, during
subsequent chemotherapy or radiotherapy, as well as reduc-
ing the tumour load requiring treatment (Green et al., 1981;
Paulson et al., 1983; Sheridan et al., 1985; Bonadonna &
Valagussa, 1986; Ampil, 1987; List et al., 1988; Haber &
Mayer, 1988; Baildam et al., 1989); whilst other investigators
have argued that this is not the case (Herrman et al., 1980;
Rao et al., 1984; Cajozzo et al., 1987; Gobbi et al., 1990). In
the present series two patients perforated, both after having
undergone radical surgery followed by chemotherapy. How-
ever three patients who were only biopsied experienced fatal
haematemesis and melaena during subsequent chemotherapy.
In addition, there was one post-operative death which occur-
red following major surgery. These results suggest that sur-
gical debulking does not necessarily protect the patients from
complications. There is also disagreement as to whether
adjuvant therapy following complete excision is necessary
(Lim et al., 1977; Herrmann et al., 1980; Gospodarowicz et
al., 1983; Kaufman et al., 1984; Rao et al., 1984; Sheridan et
al., 1985; Bonadonna & Valagussa, 1986; Kajanti et al., 1988;
Jones et al., 1988; Haber & Mayer, 1988; Mentzer et al.,
1988). It is of interest that in the present study, patients who
received chemotherapy had a worrying incidence of side
effects: of the 15 patients who died with infection, 12 were
receiving chemotherapy at the time.
Individual centres see only small numbers of patients with
GIT lymphoma over a long period, and there is therefore a
need for a multicentre prospective study in order to create a
database large enough for definitive analyses to be made in
order to rationalise the treatment of such patients.
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